Resilience. Results. Remission.
2017 Annual Report
The Exelixis 2017 Annual Report emphasizes the collaborative approach that drives our mission to help cancer patients recover stronger and live longer.
Download a PDF copy of the 2017 Annual Report
Letter to Stockholders
Exelixis President and CEO Michael M. Morrissey, Ph.D., provides an overview of the company’s performance in 2017 and discusses the company’s values that will lead Exelixis forward.
View the Letter to Stockholders
Rob and Cindy’s Treatment Journey
Learn about the resilience of a patient with advanced kidney cancer who committed to achieving the personal and professional goals he set before his diagnosis, and who continues to thrive with the support of his wife and caregiver.
Exelixis Culture and Values
Six Exelixis team members reflect on the unique culture and values that position Exelixis for success in 2018 and beyond.
Our pipeline includes our lead compounds, as well as other programs that are the subject of partnerships and collaborations with several biopharmaceutical companies.